Understanding how tumor environments cause treatment resistance in glioblastoma
Official title: Defining Tumor Microenvironmental Interactions that drive THY1-Mediated Treatment Resistance in Glioblastoma
Funded at University of Michigan at Ann Arbor · NIH-11042243 · Data updated 2026-11-12
This study is looking at how the environment around glioblastoma tumors affects their resistance to treatment, with the goal of finding new therapies that can help patients get better.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | March 1, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $233,280 |
| NIH project number | 5K08NS128271-02 |
| Project ID | NIH-11042243 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with glioblastoma who are seeking innovative treatment options.
✕Less likely to help
Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
What this research studies
This research investigates the interactions within the tumor microenvironment that contribute to treatment resistance in glioblastoma, a type of brain cancer. By utilizing advanced modeling techniques and cancer genomics, the research aims to identify specific cellular interactions that hinder effective treatment. Patients may benefit from this research as it seeks to develop targeted therapies that can overcome these resistance mechanisms, potentially leading to improved outcomes. The research is led by Dr. Wajd Al-Holou at the University of Michigan, who is training under esteemed mentors in the field.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively target treatment-resistant glioblastoma.
How similar studies have gone: Previous research has shown promise in understanding tumor microenvironment interactions, suggesting that this approach could lead to significant advancements in glioblastoma treatment.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Al-Holou, Wajd — University of Michigan at Ann Arbor
- Study coordinator: Al-Holou, Wajd
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.